0001179110-14-002710.txt : 20140213 0001179110-14-002710.hdr.sgml : 20140213 20140213160744 ACCESSION NUMBER: 0001179110-14-002710 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20131202 FILED AS OF DATE: 20140213 DATE AS OF CHANGE: 20140213 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: MERRIMACK PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001274792 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: ONE KENDALL SQUARE STREET 2: SUITE B7201 CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 617-441-1000 MAIL ADDRESS: STREET 1: ONE KENDALL SQUARE STREET 2: SUITE B7201 CITY: CAMBRIDGE STATE: MA ZIP: 02139 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Mulroy Robert J. CENTRAL INDEX KEY: 0001531563 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35409 FILM NUMBER: 14606118 MAIL ADDRESS: STREET 1: MERRIMACK PHARMACEUTICALS, INC. STREET 2: ONE KENDALL SQUARE, SUITE B7201 CITY: CAMBRIDGE STATE: MA ZIP: 02139 4 1 edgar.xml FORM 4 - X0306 4 2013-12-02 0 0001274792 MERRIMACK PHARMACEUTICALS INC MACK 0001531563 Mulroy Robert J. C/O MERRIMACK PHARMACEUTICALS, INC. ONE KENDALL SQUARE, SUITE B7201 CAMBRIDGE MA 02139 1 1 0 0 President and CEO Common Stock 2013-12-02 5 W 0 E 58290 0 D 931354 I By Trust Common Stock 2013-12-02 5 W 0 E 9715 0 A 941069 D Stock Option (right to buy) 5.02 2014-02-11 4 A 0 300000 0 A 2024-02-10 Common Stock 300000 300000 D The reporting person was previously a trustee of a trust created as a result of a bequest. All shares of the issuer held by such trust were previously reported as beneficially owned by the reporting person on a Form 4 filed on 2/13/13. The reported transactions represent the dissolution of such trust and the distribution of a portion of the shares held by such trust to the reporting person. The shares that were distributed to other beneficiaries are not reportable by the reporting person. This option vests as to 1/12th of the total number of shares on 5/11/14 and an additional 1/12th of the total number of shares at the end of each successive three month period thereafter until 2/11/17. /s/ Jeffrey A. Munsie, attorney-in-fact 2014-02-13